Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct 1:150:13S-19S.
doi: 10.1097/PRS.0000000000009495. Epub 2022 Sep 28.

Long-Term Cancer Recurrence Rates following Nipple-Sparing Mastectomy: A 10-Year Follow-Up Study

Carter J Boyd  1 , Ara A Salibian  1 , Jonathan M Bekisz  1 , Deborah M Axelrod  1 , Amber A Guth  1 , Richard L Shapiro  1 , Freya R Schnabel  1 , Nolan S Karp  1 , Mihye Choi  1
Affiliations

Long-Term Cancer Recurrence Rates following Nipple-Sparing Mastectomy: A 10-Year Follow-Up Study

Carter J Boyd et al. Plast Reconstr Surg. .

Abstract

Background: Despite the increased use of nipple-sparing mastectomies, there are limited data examining long-term cancer recurrence rates in these patients. The objective of this study was to analyze breast cancer recurrence in patients who underwent therapeutic nipple-sparing mastectomy with a median of 10 years of follow-up.

Methods: All patients undergoing nipple-sparing mastectomy at a single institution were retrospectively reviewed temporally to obtain a median of 10 years of follow-up. Patient demographic factors, mastectomy specimen pathologic findings, and oncologic outcomes were analyzed. Univariate analysis was performed to identify independent risk factors for locoregional recurrence.

Results: One hundred twenty-six therapeutic nipple-sparing mastectomies were performed on 120 patients. The most frequently observed tumor histology included invasive ductal carcinoma (48.4 percent) and ductal carcinoma in situ (38.1 percent). Mean tumor size was 1.62 cm. Multifocal or multicentric disease and lymphovascular invasion were present in 31.0 percent and 10.3 percent of nipple-sparing mastectomy specimens, respectively. Sentinel lymph node biopsy was performed in 84.9 percent of nipple-sparing mastectomies, and 17.8 percent were positive. The rate of positive frozen subareolar biopsy was 7.3 percent ( n = 82) and that of permanent subareolar pathology was 9.5 percent ( n = 126). The most frequently observed pathologic tumor stages were stage I (44.6 percent) and stage 0 (33.9 percent). The incidence of recurrent disease was 3.17 percent per mastectomy and 3.33 percent per patient. On univariate analysis, no demographic, operative, or tumor-specific variables were independent risk factors for locoregional recurrence.

Conclusions: Overall recurrence rates are low in patients undergoing nipple-sparing mastectomy at a median follow-up of 10-years. Close surveillance should remain a goal for patients and their providers to promptly identify potential recurrence.

Clinical question/level of evidence: Risk, III.

PubMed Disclaimer

References

    1. Sisco M, Kyrillos AM, Lapin BR, Wang CE, Yao KA. Trends and variation in the use of nipple-sparing mastectomy for breast cancer in the United States. Breast Cancer Res Treat. 2016;160:111–120.
    1. Valero MG, Muhsen S, Moo TA, et al. Increase in utilization of nipple-sparing mastectomy for breast cancer: Indications, complications, and oncologic outcomes. Ann Surg Oncol. 2020;27:344–351.
    1. Frey JD, Salibian AA, Lee J, et al. Oncologic trends, outcomes, and risk factors for locoregional recurrence: An analysis of tumor-to-nipple distance and critical factors in therapeutic nipple-sparing mastectomy. Plast Reconstr Surg. 2019;143:1575–1585.
    1. Shimo A, Tsugawa K, Tsuchiya S, et al. Oncologic outcomes and technical considerations of nipple-sparing mastectomies in breast cancer: Experience of 425 cases from a single institution. Breast Cancer 2016;23:851–860.
    1. Yamashita Y, Tsunoda H, Nagura N, et al. Long-term oncologic safety of nipple-sparing mastectomy with immediate reconstruction. Clin Breast Cancer 2021;21:352–359.